Restless legs syndrome (RLS) is a neurological disease. RLS is also called as Willis-Ekbom disease. Patients suffering from RLS disease have an irresistible desire to move their feet. The continual movement of the legs leads to pain in the limbs, which leads to the unusual sleep pattern of patients.
According to our (Global Info Research) latest study, the global Restless Legs Syndrome market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.
Global key players of Restless Legs Syndrome include Boehringer Ingelheim GmbH, UCB SA, Astellas, Arbor Pharmaceuticals, etc.
Boehringer Ingelheim GmbH is the largest manufacturers of Restless Legs Syndrome in the world, has a share about 70%.
This report is a detailed and comprehensive analysis for global Restless Legs Syndrome market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Restless Legs Syndrome market size and forecasts, in consumption value ($ Million), 2019-2030
Global Restless Legs Syndrome market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Restless Legs Syndrome market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Restless Legs Syndrome market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Restless Legs Syndrome
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Restless Legs Syndrome market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Boehringer Ingelheim GmbH, UCB SA, Astellas, Arbor Pharmaceuticals, GlaxoSmithKline plc., Ligand Pharmaceuticals Incorporated, axxonis Pharma AG, Kyowa Hakko Kirin Co., Jazz Pharmaceuticals, Inc., Omeros Corporation, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Restless Legs Syndrome market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segmentation
Restless Legs Syndrome market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Pharmacological Therapy
Non-Pharmacological Therapy
Market segment by Application
Below 35 Years Old
From 35 to 50 Years Old
Above 50 Years Old
Market segment by players, this report covers
Boehringer Ingelheim GmbH
UCB SA
Astellas
Arbor Pharmaceuticals
GlaxoSmithKline plc.
Ligand Pharmaceuticals Incorporated
axxonis Pharma AG
Kyowa Hakko Kirin Co.
Jazz Pharmaceuticals, Inc.
Omeros Corporation
Manhattan Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Restless Legs Syndrome product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Restless Legs Syndrome, with revenue, gross margin, and global market share of Restless Legs Syndrome from 2019 to 2024.
Chapter 3, the Restless Legs Syndrome competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Restless Legs Syndrome market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Restless Legs Syndrome.
Chapter 13, to describe Restless Legs Syndrome research findings and conclusion.
Summary:
Get latest Market Research Reports on Restless Legs Syndrome. Industry analysis & Market Report on Restless Legs Syndrome is a syndicated market report, published as Global Restless Legs Syndrome Market 2024 by Company, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of Restless Legs Syndrome market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.